Nanobiose

Nanobiose is aimed at customers in the pharmaceutical, biotechnological and cosmetics fields of industries who suffer from a lack of efficient and predictive tools to evaluate the safety of their products at early stages.

Safety and toxicity risks are badly evaluated along with the R&D process, leading to delays, extra costs, poor allocation of resources, delayed time to market and ROI, etc. Finally, 50% of drugs entering into phase III clinical trials fail, among which 30% for a safety / toxicity reason not detected in early stages of development.

Nanobiose offers solutions for more predictive in vitro safety evaluation of innovative healthcare products be it drugs, nanomedicines, therapeutic antibodies or proteins, chemicals, constrat agents and cosmetics.

Nanobiose develops a lab-on-a-chip solution which combines both microfluidics, allowing perfusion of samples, 3D cell culture, mimicking better the physiological environment in the body and on-line biomarkers secretion capture for real-time analysis.

This provides researchers with a unique tool which allow them to simultaneously observe and detect the impact of both the cytotoxic potential of the tested items but also their ability to elicit / inhibit specific biomarkers responses.